KLI
SRPT icon

Kelman-Lazarov Inc’s Sarepta Therapeutics SRPT Stock Holding History

Kelman-Lazarov Inc’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-250
Closed -$5.06K – 392
2016
Q2 		$5.06K Hold
250
– – ﹤0.01% 311
2016
Q1 		$5K Buy
+250
New +$4.37K ﹤0.01% 307

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Kelman-Lazarov Inc's SRPT Position: Q3 2016 in Review

Kelman-Lazarov Inc sold out of Sarepta Therapeutics (SRPT) in Q3 2016, closing a stake of 250 shares — an estimated $5.06K sold.

Kelman-Lazarov Inc first reported a position in SRPT in Q1 2016 and held it in 2 quarters. The position peaked at $5.06K in Q2 2016. 186 funds tracked by Wall St. Rank hold SRPT as of Q3 2016.

  • Kelman-Lazarov Inc reported no remaining Sarepta Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Kelman-Lazarov Inc sold 250 Sarepta Therapeutics shares in Q3 2016, an estimated $5.06K.
  • Kelman-Lazarov Inc first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 2 quarters.
  • Kelman-Lazarov Inc's Sarepta Therapeutics position peaked at $5.06K in Q2 2016.
  • 186 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2016.

Based on Kelman-Lazarov Inc's 13F filing for Q3 2016, filed 11 Oct 2016.